Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 6/20 | 0.64 |
| ▸ | CRHR2 | Q13324 | 6/20 | 0.64 |
| ▸ | MCOLN3 | Q8TDD5 | 6/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | MCOLN2 | Q8IZK6 | 6/20 | 0.51 |
| ▸ | MCOLN1 | Q9GZU1 | 6/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6306235 | 1.00 | CRHBP (0.64) | CRHBPCRHR2MCOLN3KMT2AMCOLN2 | |
| SCHEMBL6303780 | 0.95 | CRHBP (0.66) | CRHBPCRHR2MCOLN3KMT2AMCOLN2 | |
| SCHEMBL6310948 | 0.95 | KMT2A (0.62) | CRHBPCRHR2MCOLN3KMT2AMCOLN2 | |
| SCHEMBL6311411 | 0.95 | KMT2A (0.60) | CRHBPCRHR2MCOLN3KMT2AMCOLN2 | |
| SCHEMBL6303763 | 0.95 | KMT2A (0.60) | CRHBPCRHR2MCOLN3KMT2AMCOLN2 | |
| SCHEMBL6303757 | 0.95 | KMT2A (0.60) | CRHBPCRHR2MCOLN3KMT2AMCOLN2 | |
| SCHEMBL6312479 | 0.95 | CRHBP (0.58) | CRHBPCRHR2MCOLN3KMT2AMCOLN2 | |
| SCHEMBL6310941 | 0.95 | KMT2A (0.62) | CRHBPCRHR2MCOLN3KMT2AMCOLN2 | |
| SCHEMBL6312476 | 0.95 | CRHBP (0.58) | CRHBPCRHR2MCOLN3KMT2AMCOLN2 | |
| SCHEMBL6303778 | 0.95 | CRHBP (0.66) | CRHBPCRHR2MCOLN3KMT2AMCOLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6977265-B2 | Piperidine CCR-3 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2005-12-20 | — | — | US | disclosed |
| US-20030229121-A1 | Piperidine CCR-3 receptor antagonists | SYNTEX (U.S.A.) LLC | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229121-A1 | Piperidine CCR-3 receptor antagonists | CCR1, CCR3, CCRL2 | CRHBP 1470/4885CRHR2 185/4885MCOLN3 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.